X
New 3-year data supports Kite ‘cure’ hopes for CAR-T
https://pharmaphorum.com/news/new-3-year-data-supports-kite-cure-hopes-car-t/
Kite Pharma
Novartis close to first-ever CAR-T approval after unanimous vote
July 13, 2017Panel unanimously back CTL019
Novartis CAR-T safety in FDA spotlight
July 11, 2017
Oxford BioMedica signs $100m CAR-T deal with Novartis
July 7, 2017UK firm to supply viruses to generate CAR-T therapies
FDA to review Novartis CAR-T next month
June 6, 2017If all goes well, FDA could approve CTL109 by late September
Novartis edges ahead in CAR-T race
March 30, 2017
Interview: Vas Narasimhan on Novartis’ goal to lead in CAR-T therapies
March 2, 2017Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Kite’s CAR-T therapy most valuable pipeline orphan drug
March 1, 2017Drug tops list compiled by Evaluate Pharma
Great news for Kite after CAR-T success in cancer patients
February 28, 2017 1 2
